Unipharma Co (ROCO:6621) Debt-to-Asset : 0.05 (As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Unipharma Co Debt-to-Asset?

Unipharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$3.71 Mil. Unipharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$11.07 Mil. Unipharma Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$328.98 Mil. Unipharma Co's debt to asset for the quarter that ended in Dec. 2024 was 0.04.

Unipharma Co Debt-to-Asset Historical Data

The historical data trend for Unipharma Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unipharma Co Debt-to-Asset Chart

Unipharma Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.04

0.02

0.01

0.05

Unipharma Co Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	-	0.05	0.05

Competitive Comparison of Unipharma Co's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Unipharma Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Unipharma Co's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Unipharma Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Unipharma Co's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Unipharma Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Unipharma Co's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.712	+	11.072)	/	328.976
	=	0.04

Unipharma Co's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(3.712	+	11.072)	/	328.976
	=	0.04

Unipharma Co (ROCO:6621) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Unipharma Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Unipharma Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Unipharma Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unipharma Co Ltd (ROCO:6621) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jiu Zong Road, 3rd Floor, No. 17, Lane 171, Section 2, NeiHu District, Taipei, TWN, 11494

Website

http://www.uni-pharma.com

Unipharma Co Ltd is a medical diagnostic, pharmaceutical and medical device company. It is engaged in developing drug products and medical equipment. The company's products offerings include Baxter, Tambocor tablets, Bain Injection, Esmolol HCL Injection, Naloxone Injection, and SAM Pelvic Sling medical device. Its customers are major medical centers, regional hospitals, regional hospitals, and clinics.

Unipharma Co Headlines

No Headlines